LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
LIGAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$297.28+1.74 (+0.59%)
Close on Oct 19, 2026
- Market cap
- $6.49B
- P/E (TTM)
- 31.6
- Dividend yield
- –
LIGAND PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $188.11M | $176.47M | $161.00M | $145.28M | $130.40M | $117.17M | $108.77M | $96.45M | $88.63M | $86.41M | $84.96M | $84.88M | 64.7% | +44.3% |
| Revenue from intangible royalty assets | $151.16M | $143.88M | $132.53M | $119.65M | $106.04M | $98.56M | $95.33M | $89.98M | $87.29M | $85.11M | $83.91M | – | 52.0% | +42.5% |
| Contract revenue | $63.36M | $62.60M | $66.87M | $8.47M | $22.19M | – | $27.48M | – | – | – | $17.98M | $18.41M | 21.8% | +185.5% |
| Filspari | $44.98M | $37.99M | $31.97M | $25.73M | $19.86M | $15.71M | $12.18M | $8.35M | $6.27M | $4.16M | $2.66M | – | 15.5% | +126.5% |
| Income from financial royalty assets | $36.95M | $32.59M | $28.47M | $25.63M | $24.36M | $18.61M | $13.44M | $6.48M | $1.35M | $1.29M | $1.05M | – | 12.7% | +51.7% |
| Captisol | $35.10M | $35.41M | $40.21M | $40.34M | $35.92M | $35.13M | $30.88M | $26.89M | $29.24M | $26.96M | $28.37M | $51.33M | 12.1% | -2.3% |
| Qarziba | $24.86M | $24.60M | $23.74M | $23.80M | $22.45M | $16.56M | $11.12M | – | – | – | – | – | 8.6% | +10.8% |
| Capvaxive | $11.21M | $11.14M | $10.06M | $6.53M | $3.76M | – | $626.00K | – | – | – | – | – | 3.9% | +198.0% |
| Vaxneuvance | $6.44M | $7.73M | $7.40M | $7.19M | $6.62M | $5.08M | $5.18M | $5.03M | $4.88M | $4.81M | $4.06M | – | 2.2% | -2.7% |
| Other | $5.75M | $4.95M | $4.73M | $1.84M | $1.92M | $2.05M | $2.32M | – | – | – | – | – | 2.0% | +200.1% |
| Milestone | – | – | – | – | – | – | – | – | – | – | $16.80M | $15.80M | – | – |
| Captisol | – | – | – | – | – | – | – | – | – | – | $28.37M | $27.75M | – | – |
| Captisol - COVID | – | – | – | – | – | – | – | – | – | – | $0 | $23.58M | – | – |
| Other | – | – | – | – | – | – | $7.49M | $7.96M | $7.60M | $7.58M | $6.76M | $9.21M | – | – |
| Contract revenue | – | – | – | – | – | – | – | – | – | – | $17.98M | – | – | – |
| Contract revenue and income | – | – | – | $65.62M | $21.26M | $29.19M | $27.48M | $29.08M | $15.61M | $4.94M | $17.98M | – | – | – |
| Income from Pelthos Transaction | – | – | $53.07M | – | – | – | $0 | – | – | – | – | – | – | – |
| Ohtuvayre | – | – | $9.76M | – | – | – | $833.00K | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Ligand Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.